We are live on ! Find out more
HRMY icon

Harmony Biosciences

247 hedge funds and large institutions have $1.82B invested in Harmony Biosciences in 2024 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 128 increasing their positions, 49 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

161% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 49

142% more call options, than puts

Call options by funds: $4.24M | Put options by funds: $1.76M

19% more capital inflows, than outflows

Capital inflows: $382M | Capital outflows: $322M

15% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 26

6% more funds holding

Funds holding: 233 → 247 (+14)

4.24% more ownership

Funds ownership: 88.26% → 92.5% (+4.2%)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
247
Holders Change
+14
Holders Change %
+6.01%
% of All Funds
3.24%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
30
Increased
128
Reduced
49
Closed
26
Calls
$4.24​M
Puts
$1.76​M
Net Calls
+$2.49​M
Net Calls Change
+$99​K

HRMY Hedge Fund Activity: Q4 2024 in Review

247 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q4 2024, worth a combined $1.82B — down 9.5% from $2.01B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new HRMY positions and 26 closed out — a net gain of 4 holders — while 128 added to existing stakes and 49 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $49.8M. The largest seller was Valor Management, cutting an estimated $158M.

  • 247 institutional investors held Harmony Biosciences (HRMY) as of Q4 2024, up from 233 in Q3 2024.
  • Funds reported $1.82B of Harmony Biosciences stock for Q4 2024, down 9.5% quarter-over-quarter.
  • 30 funds opened new Harmony Biosciences positions in Q4 2024 and 26 closed out, a net change of +4 holders.
  • The largest Harmony Biosciences buyer in Q4 2024 was Deep Track Capital, an estimated $49.8M added.
  • The largest Harmony Biosciences seller in Q4 2024 was Valor Management, an estimated $158M sold.

Based on aggregated 13F filings for Q4 2024.